Press Releases - Emmaus Medical, Inc.

Emmaus Life Sciences Provides Interim Sales InformationJuly 22, 2021

Emmaus Life Sciences, Inc. announced today preliminary sales results for the six months ended June 30, 2021.

Emmaus Life Sciences Announces Submission of Endari Marketing Authorization Application in KuwaitJuly 15, 2021

Emmaus Life Sciences, Inc. (OTC: EMMA) announced today the submission of its application for Marketing Authorization (MA) for Endari® to the Kuwait Drug and Food Control (KDFC).

Emmaus Life Sciences Announces Submission of Marketing Authorization Application to SwissmedicJune 15, 2021

Emmaus Life Sciences, Inc announced today it has received confirmation from the Swiss Agency for Therapeutic Products (Swissmedic) of Emmaus’ application for Marketing Authorization (MA) for Endari® in Switzerland.

Emmaus Life Sciences Announces Submission of Marketing Authorization Application for Endari to the Saudi Food and Drug AuthorityMay 26, 2021

Emmaus Life Sciences announced today that its application for Marketing Authorization (MA) for Endari® in the Kingdom of Saudi Arabia has been accepted by the Saudi Food and Drug Authority (SFDA).

Emmaus Life Sciences Reports Annual Financial Results for 2020 and Provides Updated Business ReviewMay 04, 2021

Emmaus Life Sciences, Inc. announced today its financial results for the year ended December 31, 2020 as reported in its Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”).